Skip to Content

'
Karen H. Lu, MD

Present Title & Affiliation

Primary Appointment

Chair, Department of Gynecologic Oncology and Reproductive Medicine, Division of Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX

Dual/Joint/Adjunct Appointment

Graduate Faculty, Regular Member, Graduate School of Biomedical Sciences. The University of Texas Health Science Center, Houston, TX

Bio Statement

Dr. Lu is Professor in the Department of Gynecologic Oncology and Reproductive Medicine and holds the H.E.B. Professorship in Cancer Research. Her main clinical interests include the surgical and medical treatment of women with ovarian and endometrial cancers, as well as the management of women at genetically high risk for these cancers. She serves as Co-Director for the MD Anderson Clinical Cancer Genetics Program and Director of the High Risk Ovarian Cancer Screening Clinic. She is a national leader in the cancer genetics field and has published seminal articles on hereditary gynecologic cancers. In addition, she serves as Director of the Uterine Cancer Research Program (UCRP) and Principal Investigator of the NCI-sponsored Uterine Cancer Specialized Program of Research Excellence (SPORE). She leads a research team that aims to apply laboratory-based findings to improving the care of gynecologic cancer patients. She receives support for her research from the National Cancer Institute, the Lynne Cohen Foundation, the American Gynecologic and Obstetric Society, and the Ovarian Cancer Research Fund. She has published numerous articles and book chapters and has served as a visiting professor at many academic institutions.  She serves on the American Society of Clinical Oncology (ASCO) Cancer Prevention Committee, the NCI PDQ Editorial Board for Cancer Genetics and the American College of Obstetricians and Gynecologists (ACOG) Committee on Gynecologic Practice Bulletins. In addition, she takes pride in having mentored many clinical fellows and trainees and has been awarded an M.D. Anderson Outstanding Educator Award. She has consistently been featured as one of America’s Top Doctors.

 

Education & Training

Degree-Granting Education

1991 Yale University School of Medicine, New Haven, CT, MD
1986 Harvard University, Cambridge, MA, BA, Biochemical Sciences, cum laude

Postgraduate Training

9/2011-4/2012 Executive Leadership in Academic Medicine (ELAM), Drexel University College of Medicine, Philadelphia, PA
11/2007-4/2008 Clinical Safety and Effectiveness Training Program, The University of Texas MD Anderson Cancer Center, Houston, TX
1996-1999 Fellowship, Gynecologic Oncology, Brigham and Women's Hospital, Harvard Medical School, Boston, Boston, MA
1991-1995 Internship and Residency, Obstetrics and Gynecology, Brigham and Women's Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA

Board Certifications

2003 American Board of Obstetrics and Gynecology, Diplomate, Div of Gynecologic Oncology
2001 American Board of Obstetrics and Gynecology, Diplomate
1992 National Board of Medical Examiners, Diplomate

Experience/Service

Academic Appointments

Professor, Department of Gynecologic Oncology and Reproductive Medicine, Division of Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX, 9/2008-10/2012
Associate Professor, Department of Gynecologic Oncology, The University of Texas M.D. Anderson Cancer Center, Houston, TX, 9/2004-8/2008
Assistant Professor, Department of Gynecologic Oncology and Reproductive Medicine, Division of Surgery, The University of Texas, M.D. Anderson Cancer Center, Houston, TX, 1999-2004
Instructor, Harvard Medical School, Boston, MA, 1995-1996

Administrative Appointments/Responsibilities

Co-Director, Clinical Cancer Genetics, The University of Texas MD Anderson Cancer Center, Houston, TX, 2006-present

Endowed Positions

H.E.B. Professorship in Cancer Research, Department of Gynecologic Oncology and Reproductive Medicine, Division of Surgery, The University of Texas M. D. Anderson Cancer Center, Houston, TX, 9/2008-7/2013

Institutional Committee Activities

Member, 2011 Faculty Achievement Awards Committee, 5/2011

Honors and Awards

2011 Finalist, Julie and Ben Rogers Award for Excellence, The University of Texas MD Anderson Cancer Center
2010 2010 Faculty Achievement Award in Cancer Prevention, MD Anderson Cancer Center, The Margaret and James A. Elkins, Jr. Faculty Achievement Award in Cancer Prevention
2009-2010 Best Doctors in America, Best Doctors
2009 America's Top Doctors for Cancer, Castle Connally Medical LTD
2007 Faculty Educator of the Month (October), UT MD Anderson Cancer Center
2007 Medical Honoree Award, Lynne Cohen Foundation
2004 Mischell Award, Wyeth Annual Therapeutic Options for Menopausal Health Confrerence
2003 Outstanding Educator Award, M.D. Anderson
2001-2004 Liz Tilberis Scholar Award, Ovarian Cancer Research Fund
1999-2002 Burroughs Wellcome Award, American Association of Obstetricians and Gynecologists Foundation (AAOGF)
1998-1999 Academic Training Award, American College of Obstetrics and Gynecology, ORTHO
1995 APGO/CREOG Parke-Davis Scholars Award
1994-1995 Administrative Chief Resident, Harvard Medical School
1990 Farr Scholar, Yale Medical School
1990 Summer Research Fellowship, Yale Medical School
1986 Radcliffe Travelling Fellowship, Harvard and Radcliffe Colleges
1986 Thomas Hoopes Prize "for outstanding undergraduate thesis", Harvard University

Selected Publications

Peer-Reviewed Original Research Articles

1. Schmeler KM, Daniels MS, Soliman PT, Broaddus RR, Deavers MT, Vu TM, Chang GJ, Lu KH. Primary Peritoneal Cancer After Bilateral Salpingo-Oophorectomy in Two Patients With Lynch Syndrome. Obstet Gynecol 115(2):432-4, 2/2010. PMCID: PMC4250042.
2. Westin SN, Broaddus RR, Deng L, McCampbell A, Lu KH, Lacour RA, Milam MR, Urbauer DL, Mueller P, Pickar JH, Loose DS. Molecular clustering of endometrial carcinoma based on estrogen-induced gene expression. Cancer Biol Ther 8(22):2126-35, 11/2009. e-Pub 11/2009. PMCID: PMC2872176.
3. Lu KH, Yates MS, Mok SC. The monkey, the hen, and the mouse: models to advance ovarian cancer chemoprevention. Cancer Prev Res (Phila Pa) 2(9):773-5, 9/2009. e-Pub 9/2009. PMID: 19737981.
4. Lu KH. Management of Early-Stage Endometrial Cancer. Semin Oncol 36(2):137-44, 4/2009. PMID: 19332248.
5. Zhang Q, Shen Q, Celestino J, Milam MR, Westin SN, Lacour RA, Meyer LA, Shipley GL, Davies PJ, Deng L, McCampbell AS, Broaddus RR, Lu KH. Enhanced estrogen-induced proliferation in obese rat endometrium. Am J Obstet Gynecol 200(2):186.e1-8, 2/2009. PMID: 19185100.
6. Basen-Engquist K, Scruggs S, Jhingran A, Bodurka DC, Lu K, Ramondetta L, Hughes D, Carmack Taylor C. Physical activity and obesity in endometrial cancer survivors: associations with pain , fatigue, and physical functioning. Am J Obstet Gynecol 200(3):288, 2009.
7. Soliman PT, Bassett RL, Wilson EB, Boyd-Rogers S, Schmeler KM, Milam MR, Gershenson DM, Lu KH. Limited public knowledge of obesity and endometrial cancer risk: what women know. Obstet Gynecol 112(4):835-42, 10/2008. PMID: 18827126.
8. Kwon JS, Sun CC, Peterson SK, White KG, Daniels MS, Boyd-Rogers SG, Lu KH. Cost-effectiveness analysis of prevention strategies for gynecologic cancers in Lynch Syndrome. Cancer 113(2):326-35, 7/15/2008. PMID: 18506736.
9. Kwon JS, Lu KH. Cost-effectiveness analysis of endometrial cancer prevention strategies for obese women. Obstet Gynecol 112(1):56-63, 7/2008. PMID: 18591308.
10. Lu KH, Wu W, Dave B, Slomovitz BM, Burke TW, Munsell MF, Broaddus RR, Walker CL. Loss of tuberous sclerosis complex-2 function and activation of mammalian target of rapamycin signaling in endometrial carcinoma. Clin Cancer Res 14(9):2543-50, 5/2008. PMID: 18451215.
11. Westin SN, Lacour RA, Urbauer DL, Luthra R, Bodurka D, Lu KH, Broaddus R. Carcinoma of the lower uterine segment: A newly described association with Lynch syndrome. J Clin Oncol 26(36):5965-71, 2008. e-Pub 11/2008. PMCID: PMC2645115.
12. Lu KH. Hereditary gynecologic cancers: differential diagnosis, surveillance, management and surgical prophylaxis. Fam Cancer 7(1):53-8, 2008. e-Pub 7/2007. PMID: 17636427.
13. Yurkovetsky Z, Ta'asan S, Skates S, Rand A, Lomakin A, Linkov F, Marrangoni A, Velikokhatnaya L, Winans M, Gorelik E, Maxwell GL, Lu K, Lokshin A. Development of multimarker panel for early detection of endometrial cancer. High diagnostic power of prolactin. Gynecol Oncol 107:58-65, 7/2007. PMCID: PMCOMC2777971.
14. Lu KH. Hereditary gynecologic cancers: differential diagnosis, surveillance, management and surgical prophylaxis. Fam Cancer 7(1):53-8, 7/2007.
15. Vogel KJ, Atchley DP, Erlichman J, Broglio KR, Ready KJ, Valero V, Amos CI, Hortobagyi GN, Lu KH, Arun B. BRCA1 and BRCA2 genetics testing in hispanic patients: mutation prevalence and evaluation of the BRCAPRO risk assessment model. J Clin Oncol 25(29):4635-41, 2007.
16. Shvartsman HS, Sun CC, Bodurka DC, Majajan V, Crispens M, Lu KH, Deavers MT, Malpica A, Silva EG, Gershenson DM. Comparison of the clinical behavior of newly diagnosed stages II-IV low-grade serous carcinoma of the ovary with that of serous ovarian tumors of low malignant potential that recur as low-grade serous carcinoma. Gynecol Oncol 105:625-9, 2007.
17. Bedrosian I, Lee C, Tucker SL, Palla SL, Lu K, Keyomarsi K. Cyclin E associated kinase activity predicts response to platinum based chemotherapy. Clin Cancer Res 13:4800-6, 2007.
18. Lu KH, Kauff ND. Does a BRCA mutation plus tamoxifen equal hysterectomy? Gynecol Oncol 104(1):3-4, 2007. PMID: 17222708.
19. Soliman PT, Lu K. Endometrial cancer associated with defective DNA mismatch repair. Obstet Gynecol Clin North Am 34:701-15, 2007.
20. Saldivar JS, Lu KH, Liang D, Gu J, Hunang M, Vlastos AT, Follen M, Wu X. Moving toward individualized therapy based on NER polymorphisms that predict platinum sensitivity in ovarian cancer patients. Gynecol Oncol 107:S223-9, 2007.
21. Bast RC Jr, Brewer M, Zou C, Hernandez MA, Daley M, Ozols R, Lu K, Lu Z, Badgwell D, Mills GB, Skates S, Zhang Z, Chan D, Lokshin A, Yu Y. Prevention and early detection of ovarian cancer: mission impossible? Cancer Res 174:91-100, 2007.
22. Lu K, Schorge JO, Rodabaugh KJ, Daniels MS, Sun CC, Soliman PT, White KG, Luthra R, Gershenson DM, Broaddus RR. Prospective determination of prevalence of Lynch Syndrome in young women with endometrial cancer. J Clin Oncol 25:58-64, 2007.
23. Milam MR, Celestino J, Wu W, Broaddus RR, Slomovitz BM, Schmeler KM, Soliman PT, Gershenson DM, Wang H, Ellsenson LH, Lu KH. Reduced progression of endometrial hyperplasia with oral mTOR inhibition in the PTEN heterozygote murine model. Am J Obstet Gynecol 196:247.el-247.el-5, 2007.
24. Wong KK, Lu KH. Significantly higher expression of ER, PR and ECAD in advanaced-stage low-grade ovarian serous carcinomas as revealed by immunohistochemical analysis. Intl J of Gynecol Pathol 26(4):404-9, 2007.
25. Milam MR, Gu J, Yang H, Celestino J, Wu W, Horwitz IB, Lacour RA, Westin SN, Gershenson DM, Wu X, Lu K. STK15 F3II Polymorphism is associated with increased uterine cancer risk: A pilot study. Gynecol Oncol 107:71-4, 2007.
26. Slomovitz BM, Sun CC, Frumovitz M, Soliman PT, Schmeler KM, Pearson HC, Berenson A, Ramirez PT, Lu KH, Bodurka DC. Are women ready for the HPV vaccine? Gynecol Oncol 103:151-4, 2006. PMID: 16551476.
27. Soliman PT, Wu D, Tortolero-Luna G, Schmeler KM, Slomovitz BM, Bray MS, Gershenson DM, Lu KH. Association between adiponectin, insulin resistance, and endometrial cancer. Cancer 106:2376-81, 2006. PMID: 16639730.
28. Uyei A, Peterson SK, Erlichman J, Broglio K, Yekell S, Schmeler K, Lu K, Meric-Bernstam F, Amos C, Strong L, Arun B. Association between clinical characteristics and risk-reduction interventions in women who underwent BRCA1 and BRCA2 testing: a single-institution study. Cancer 107:2745-51, 2006. PMID: 17109443.
29. Gershenson DM, Sun CC, Lu KH, Coleman RL, Sood AK, Malpica A, Deavers MT, Silva EG, Bodurka DC. Clinical behavior of stage II-IV low-grade serous carcinoma of the ovary. Obstet Gynecol 108:361-8, 2006. PMID: 16880307.
30. Wu W, Slomovitz BM, Soliman PT, Schmeler KM, Celestino J, Milam MR, Lu KH. Correlation of cyclin D1 and cyclin D3 overexpression with the loss of PTEN expression in endometrial carcinoma. Int J Gynecol Cancer 16:1668-72, 2006. PMID: 16884382.
31. Chatterjee M, Mohapatra S, Ionan A, Bawa G, Ali-Fehmi R, Wang X, Nowak J, Ye B, Nahhas FA, Lu K, Witkins SS, Fishman D, Munkarah A, Morris R, Levin NK, Shirley NN, Tromp G, Abrams J, Draghici S, Tainsky MA. Diagnostic markers of ovarian cancer by high-throughput antigen cloning and detection on arrays. Cancer Res 66:1182-90, 2006.
32. Lee Z, Swaby RF, Liang Y, Yu S, Liu S, Lu KH, Bast RC, Jr, Mills GB, Fang X. Lysophosphatidic acid is a major regulator of growth-regulated oncogene alpha in ovarian cancer. Cancer Res 66:2740-8, 2006. PMID: 16510595.
33. Broaddus RR, Lynch HT, Chen LM, Daniels MS, Conrad P, Munsell MF, White KG, Luthra R, Lu KH. Pathologic features of endometrial carcinoma associated with HNPCC: a comparison with sporadic endometrial carcinoma. Cancer 106:87-94, 2006. PMID: 16323174.
34. Kelloff GJ, Lippman SM, Dannenberg AJ, Sigman CC, Pearce HL, Reid BJ, Szabo E, Jordan VC, Spitz MR, Mills GB, Papadimitrakopoulou VA, Lotan R, Aggarwal BB, Bresalier RS, Kim J, Arun B, Lu KH, Thomas ME, Rhodes HE, Brewer MA, Follen M, Shin DM, Parnes HL, Siegfried JM, Evans AA, Blot WJ, Chow WH, Blount PL, Maley CC, Wang KK, Lam S, Lee JJ, Dubinett SM, Engstrom PF, Meyskens FL, Jr, O'Shaughnessy J, Hawk ET, Levin B, Nelson WG, Hong WK. Progress in chemoprevention drug development: the promise of molecular biomarkers for prevention of intraepithelial neoplasia and cancer--a plan to move forward. Clin Cancer Res 12:3661-97, 2006. PMID: 16778094.
35. Schmeler KM, Sun CC, Bodurka DC, White KG, Soliman PT, Uyei AR, Erlichman JL, Arun BK, Daniels MS, Rimes SA, Peterson SK, Slomovitz BM, Milam MR, Gershenson DM, Lu KH. Prophylactic Bilateral Salpingo-Oophorectomy Compared With Surveillance in Women With BRCA Mutations. Obstet Gynecol 108:515-520, 2006. PMID: 16946209.
36. Schmeler K, Lynch H, Chen L, Munsell M, Soliman P, Clark M, White K, Boyd-Rogers S, Conrad P, Yang K, Rubin M, Sun C, Slomovitz B, Gershenson D, Lu K. Prophylactic surgery for the reduction of gynecologic cancer risk in women with Lynch Syndrome (HNPCC). N Eng J of Med 354:261-9, 2006.
37. Lindor NM, Petersen GM, Hadley DW, Kinney AY, Miesfeldt S, Lu K, Lynch P, Burke W, Press N. Recommendations for the care of individuals with an inherited predisposition to cancer: Hereditary nonpolyposis colorectal cancer (Lynch Syndrome). JAMA 296:1507-17, 2006.
38. Schmandt RE, Bennett M, Clifford S, Thornton A, Jiang F, Broaddus RR, Sun CC, Lu KH, Sood AK, Gershenson DM. The BRK tyrosine kinase is expressed in high-grade serous carcinoma of the ovary. Cancer Biol Ther 5:1136-41, 2006. PMID: 16855388.
39. Broaddus RR, Lu KH. Women with HNPCC: a target population for the chemoprevention of gynecologic cancers. Front Biosci 11:2077-80, 2006. PMID: 16720294.
40. Eder AM, Sui X, Rosen DG, Nolden LK, Cheng KW, Lahad JP, Kango-Singh M, Lu KH, Warneke CL, Atkinson EN, Bedrosian I, Keyomarsi K, Kuo WL, Gray JW, Yin JC, Liu J, Halder G, Mills GB. Atypical PKCiota contributes to poor prognosis through loss of apical-basal polarity and cyclin E overexpression in ovarian cancer. Proc Natl Acad Sci U S A 102:12519-24, 2005. PMID: 16116079.
41. Schmeler KM, Soliman PT, Sun CC, Slomovitz BM, Gershenson DM, Lu KH. Endometrial cancer in young, normal-weight women. Gynecol Oncol 99:388-92, 2005. PMID: 16051336.
42. Bonome T, Lee JY, Park DC, Radonovich M, Pise-Masison C, Brady J, Gardner GJ, Hao K, Wong WH, Barrett JC, Lu KH, Sood AK, Gershenson DM, Mok SC, Birrer MJ. Expression profiling of serous low malignant potential, low-grade, and high-grade tumors of the ovary. Cancer Res 65:10602-12, 2005. PMID: 16288054.
43. Broaddus RR, Lu KH. Future challenges in clinical and translational research for endometrial cancer. Int J Gyn Cancer 15:398, 2005.
44. Hartmann LC, Lu KH, Linette GP, Cliby WA, Kalli KR, Gershenson D, Bast RC, Stec J, Iartchouk N, Smith DI, Ross JS, Hoersch S, Shridhar V, Lillie J, Kaufmann SH, Clark EA, Damokosh AI. Gene expression profiles predict early relapse in ovarian cancer after platinum-paclitaxel chemotherapy. Clin Cancer Res 11:2149-55, 2005. PMID: 15788660.
45. Lu KH, Dinh M, Kohlmann W, Watson P, Green J, Syngal S, Bandipalliam P, Chen LM, Allen B, Conrad P, Terdiman J, Sun C, Daniels M, Burke T, Gershenson DM, Lynch H, Lynch P, Broaddus RR. Gynecologic cancer as a "sentinel cancer" for women with hereditary nonpolyposis colorectal cancer syndrome. Obstet Gynecol 105:569-74, 2005. PMID: 15738026.
46. Lu, K, Broaddus R. Gynecologic cancers in Lynch Syndrome/HNPCC. Familial Cancer 4:249-254, 2005.
47. Slomovitz BM, Ramondetta LM, Lee CM, Oh JC, Eifel PJ, Jhingran A, Burke TW, Gershenson DM, Lu KH. Heterogeneity of stage IIIA endometrial carcinomas: implications for adjuvant therapy. Int J Gynecol Cancer 15:510-6, 2005. PMID: 15882178.
48. Caudell JJ, Deavers MT, Slomovitz BM, Lu KH, Broaddus RR, Gershenson DM, Ramondetta LM. Imatinib mesylate (gleevec)--targeted kinases are expressed in uterine sarcomas. Appl Immunohistochem Mol Morphol 13:167-70, 2005. PMID: 15894930.
49. Cheng YC, Saliba RM, Rondon G, Giralt SA, Lu KH, Bodurka DC, Gershenson DM, Champlin RE, Ueno NT. Low prevalence of premature ovarian failure in women given reduced-intensity conditioning regimens for hematopoietic stem-cell transplantation. Haematologica 90:1725-6, 2005. PMID: 16330461.
50. Liu Z, Wang LE, Wang L, Lu KH, Mills GB, Bondy ML, Wei Q. Methylation and messenger RNA expression of p15INK4b but not p16INK4a are independent risk factors for ovarian cancer. Clin Cancer Res 11:4968-76, 2005. PMID: 16000597.
51. Bast RC Jr, Badgwell D, Lu Z, Marquez R, Rosen D, Liu J, Baggerly KA, Atkinson EN, Skates S, Zhang Z, Lokshin A, Menon U, Jacobs I, Lu K. New tumor markers: CA126 and beyond. Int J Gynl Cancer 3:274-81, 2005.
52. Marquez RT, Baggerly KA, Patterson AP, Liu J, Broaddus R, Frumovitz M, Atkinson EN, Smith DI, Hartmann L, Fishman D, Berchuck A, Whitaker R, Gershenson DM, Mills GB, Bast RC, Jr, Lu KH. Patterns of gene expression in different histotypes of epithelial ovarian cancer correlate with those in normal fallopian tube, endometrium, and colon. Clin Cancer Res 11:6116-26, 2005. PMID: 16144910.
53. Rosen DG, Wang L, Atkinson JN, Yu Y, Lu KH, Diamandis EP, Hellstrom I, Mok SC, Liu J, Bast RC, Jr. Potential markers that complement expression of CA125 in epithelial ovarian cancer. Gynecol Oncol 99:267-77, 2005. PMID: 16061277.
54. Lee CM, Slomovitz BM, Greer M, Sharma S, Gregurich MA, Burke T, Lu KH, Ramondetta LM. Practice patterns of SGO members for stage IIIA endometrial cancer. Gynecol Oncol 98:77-83, 2005. PMID: 15907988.
55. Soliman PT, Oh JC, Schmeler KM, Sun CC, Slomovitz BM, Gershenson DM, Burke TW, Lu KH. Risk factors for young premenopausal women with endometrial cancer. Obstet Gynecol 105:575-80, 2005. PMID: 15738027.
56. Lu KH, Gershenson DM. Update on the management of ovarian germ cell tumors. J Reprod Med 50:417-25, 2005. PMID: 16050566.
57. Soliman PT, Broaddus RR, Schmeler KM, Daniels MS, Gonzalez D, Slomovitz BM, Gershenson DM, Lu KH. Women with synchronous primary cancers of the endometrium and ovary: do they have Lynch syndrome? J Clin Oncol 23:9344-50, 2005. PMID: 16361634.
58. Bedrosian I, Lu KH, Verschraegen C, Keyomarsi K. Cyclin E deregulation alters the biologic properties of ovarian cancer cells. Oncogene 23:2648-57, 2004. PMID: 15007381.
59. Slomovitz BM, Sun CC, Ramirez PT, Bodurka DC, Diaz P, Lu KH. Does tamoxifen use affect prognosis in breast cancer patients who develop endometrial cancer? Obstet Gynecol 104:255-60, 2004. PMID: 15291996.
60. Slomovitz BM, Broaddus RR, Schmandt R, Wu W, Oh JC, Ramondetta LM, Burke TW, Gershenson DM, Lu KH. Expression of imatinib mesylate-targeted kinases in endometrial carcinoma. Gynecol Oncol 95:32-6, 2004. PMID: 15385107.
61. Rosen DG, Wang L, Jain AN, Lu KH, Luo RZ, Yu Y, Liu J, Bast RC, Jr. Expression of the tumor suppressor gene ARHI in epithelial ovarian cancer is associated with increased expression of p21WAF1/CIP1 and prolonged progression-free survival. Clin Cancer Res 10:6559-66, 2004. PMID: 15475444.
62. Malpica, A, Deavers MT, Lu K, Bodurka DC, Atkinson EN, Gershenson DM, Silva EG. Grading ovarian serous carcinoma using a two-tier system. Am J Surg Path 28:496-504, 2004.
63. Slomovitz BM, Broaddus RR, Burke TW, Sneige N, Soliman PT, Wu W, Sun CC, Munsell MF, Gershenson DM, Lu KH. Her-2/neu overexpression and amplification in uterine papillary serous carcinoma. J Clin Oncol 22:3126-32, 2004. PMID: 15284264.
64. Oh JC, Wu W, Tortolero-Luna G, Broaddus R, Gershenson DM, Burke TW, Schmandt R, Lu KH. Increased plasma levels of insulin-like growth factor 2 and insulin-like growth factor binding protein 3 are associated with endometrial cancer risk. Cancer Epidemiol Biomarkers Prev 13:748-52, 2004. PMID: 15159305.
65. Lu KH, Patterson AP, Wang L, Marquez RT, Atkinson EN, Baggerly KA, Ramoth LR, Rosen DG, Liu J, Hellstrom I, Smith D, Hartmann L, Fishman D, Berchuck A, Schmandt R, Whitaker R, Gershenson DM, Mills GB, Bast RC, Jr. Selection of potential markers for epithelial ovarian cancer with gene expression arrays and recursive descent partition analysis. Clin Cancer Res 10:3291-300, 2004. PMID: 15161682.
66. Soliman PT, Slomovitz BM, Broaddus RR, Sun CC, Oh JC, Eifel PJ, Gershenson DM, Lu KH. Synchronous primary cancers of the endometrium and ovary: a single institution review of 84 cases. Gynecol Oncol 94:456-62, 2004. PMID: 15297188.
67. Cheng KW, Lahad JP, Kuo WL, Lapuk A, Yamada K, Auersperg N, Liu J, Smith-McCune K, Lu KH, Fishman D, Gray JW, Mills GB. The RAB25 small GTPase determines aggressiveness of ovarian and breast cancers. Nat Med 10:1251-6, 2004. PMID: 15502842.
68. Broaddus RR, Lynch PM, Lu KH, Luthra R, Michelson SJ. Unusual tumors associated with the hereditary nonpolyposis colorectal cancer syndrome. Mod Pathol 17:981-9, 2004. PMID: 15143336.
69. Lee CM, Shvartsman H, Deavers MT, Wang SC, Xia W, Schmandt R, Bodurka DC, Atkinson EN, Malpica A, Gershenson DM, Hung MC, Lu KH. beta-catenin nuclear localization is associated with grade in ovarian serous carcinoma. Gynecol Oncol 88:363-8, 2003. PMID: 12648588.
70. Slomovitz BM, Burke TW, Oh J, Broaddus RR, Eifel PJ, Atkinson EN, Silva EG, Gershenson DM, Lu KH. Clinical and pathologic characteristics of uterine papillary serous carcinoma (UPSC): A single institution review of 129 cases. Gynecologic Oncology 91:463-69, 2003.
71. Wu W, Slomovitz BM, Celestino J, Chung L, Thornton A, Lu KH. Coordinate expression of Cdc25B and ER-alpha is frequent in low-grade endometrioid endometrial carcinoma but uncommon in high-grade endometrioid and nonendometrioid carcinomas. Cancer Res 63:6195-9, 2003. PMID: 14559803.
72. Schmandt RE, Broaddus R, Lu KH, Shvartsman H, Thornton A, Malpica A, Sun C, Bodurka DC, Gershenson DM. Expression of c-ABL, c-KIT, and platelet-derived growth factor receptor-beta in ovarian serous carcinoma and normal ovarian surface epithelium. Cancer 98:758-64, 2003. PMID: 12910520.
73. Kim JH, Herlyn D, Wong KK, Park DC, Schorge JO, Lu KH, Skates SJ, Cramer DW, Berkowitz RS, Mok SC. Identification of epithelial cell adhesion molecule autoantibody in patients with ovarian cancer. Clin Cancer Res 9:4782-91, 2003. PMID: 14581349.
74. Bast Jr RC, Urban N, Shridhar V, Smith D, Zhang Z, Skates S, Lu K, Liu J, Fishman D, Mills G. Early detection of ovarian cancer: Promise and reality. Cancer Treat Res 107:61-97, 2002. PMID: 11775462.
75. Deavers MT, Gershenson DM, Tortolero-Luna G, Malpica A, Lu KH, Silva EG. Micropapillary and cribriform patterns in ovarian serous tumors of low malignant potential: a study of 99 advanced stage cases. Am J Surg Pathol 26:1129-41, 2002. PMID: 12218569.
76. Schilder JM, Thompson AM, DePriest PD, Ueland FR, Cibull ML, Kryscio RJ, Modesitt SC, Lu KH, Geisler JP, Higgins RV, Magtibay PM, Cohn DE, Powell MA, Chu C, Stehman FB, van Nagell J. Outcome of reproductive age women with stage IA or IC invasive epithelial ovarian cancer treated with fertility-sparing therapy. Gynecol Oncol 87:1-7, 2002. PMID: 12468335.
77. Crispens MA, Bodurka D, Deavers M, Lu K, Silva EG, Gershenson DM. Response and survival in patients with progressive or recurrent serous ovarian tumors of low malignant potential. Obstetrics & Gynecolog 99:3-10, 2002.
78. Shridhar V, Lee J, Pandita A, Iturria S, Avula R, Staub J, Morrissey M, Calhoun E, Sen A, Kalli K, Keeney G, Roche P, Cliby W, Lu K, Schmandt R, Mills GB, Bast RC, Jr, James CD, Couch FJ, Hartmann LC, Lillie J, Smith DI. Genetic analysis of early- versus late-stage ovarian tumors. Cancer Research 61:5895-904, 2001.
79. Lu KH, Broaddus RR. Gynecological tumors in hereditary nonpolyposis colorectal cancer: We know they are common-now what? Gynecol Oncol 82:221-2, 2001. PMID: 11531270.
80. Azevedo P, Verschraegen, CF, Kavanagh JJ, Kudelka AP, Freedman RS, Lu K, Deavers MT. Malignant mixed mesodermal tumor of the ovary treated with a cisplatin-irinotecan combination: case report. European Journal of Gynaecological Oncology 22:319-21, 2001.
81. Suzuki ,S, Moore DH, 2nd, Ginzinger DG, Godfrey TE, Barclay J, Powell B, Pinkel D, Zaloudek C, Lu K, Mills G, Berchuck A, Gray JW. An approach to analysis of large-scale correlations between genome changes and clinical endpoints in ovarian cancer. Cancer Research 60:5382-5, 2000.
82. Lu KH, Burke TW. Early cervical cancer. Curr Treat Options Oncol 1:147-55, 2000. PMID: 12057052.
83. Hoyte L, Lu K, Muto M, Nucci M, Versi E, Kikinis R, Fielding J. Magnetic resonance impaging based three dimensional modeling of a comple vulvar tumor as a component of presurgical planning. Journal of Women's Imaging: 2:138-40, 2000.
84. Lu KH, Garber JE, Cramer DW, Welch WR, Niloff J, Schrag D, Berkowitz RS, Muto MG. Occult ovarian tumors in women with BRCA1 or BRCA2 mutations undergoing prophylactic oophorectomy. J Clin Oncol 18:2728-32, 2000. PMID: 10894872.
85. Tuncer ZS, Bernstein MR, Goldstein DP, Lu KH, Berkowitz RS. Outcome of pregnancies occurring within 1 year of hydatidiform mole. Obstet Gynecol 94(4):588-90, 10/1999. PMID: 10511364.
86. Garner EI, Chang-Lee WY, Lu KH, Goldstein DP, Berkowitz RS. Trophoblastic pulmonary embolization after hysterectomy for invasive complete mole. A case report. J Reprod Med 44(10):908-12, 10/1999. PMID: 10554759.
87. Lu KH, Cramer DW, Muto MG, Li EY, Niloff J, Mok SC. A population-based study of BRCA1 and BRCA2 mutations in Jewish women with epithelial ovarian cancer. Obstet Gynecol 93(1):34-7, 1/1999. PMID: 9916952.
88. Lu KH, Bell DA, Welch WR, Berkowitz RS, Mok SC. Evidence for the multifocal origin of bilateral and advanced human serous borderline ovarian tumors. Cancer Res 58(11):2328-30, 6/1/1998. PMID: 9622067.
89. Lu KH, Weitzel JN, Kodali S, Welch WR, Berkowitz RS, Mok SC. A novel 4-cM minimally deleted region on chromosome 11p15.1 associated with high grade nonmucinous epithelial ovarian carcinomas. Cancer Res 57(3):387-90, 2/1/1997. PMID: 9012461.
90. Williams DA, Hsieh K, DeSilva A, Mulligan RC. Protection of bone marrow transplant recipients from lethal doses of methotrexate by the generation of methotrexate-resistant bone marrow. J Exp Med 166:210-8, 1987. PMID: 3298524.

Invited Articles

1. Lu KH. "Best Health", Endometrial Cancer Related Links. U.S. News & World Report, 1/2007.
2. Lu KH. Update in Gynecologic Cancer. OBG Management, 2006.
3. Lu KH. Update in Gynecologic Cancer. OBG Management, 2005.
4. Lu KH, Burke TW. Early cervical cancer. Current Treatment Options in Oncology 1(2):147-55, 6/2000.
5. Lu KH, Gershenson DM. Management of borderline ovarian tumors. Contemporary OB/GYN 45:89-100, 2000.
6. Lu KH, Goldstein DP, Bernstein MR, Berkowitz RS. Clinical decisions in gestational trophoblastic diseases. Contemporary OB/GYN, 1999.
7. Lu KH, Goldstein DP, Bernstein MR, Berkowitz RS. Managing molar pregnancies. OBG Management, 1999.
8. Lu KH, Edelson MI, Rodabaugh KJ, Wertheim I, Colitti CV, Bell DA, Welch WR, Berkowitz RS, Mok SC. Pathogenesis of borderline ovarian tumors. Proc AACR 40:760-761, 1999.

Editorials

1. Lu KH, Kauff ND. Does a BRCA mutation plus tamoxifen equal hysterectomy? Gynecol Oncol 104(1)(1):3-4, 1/2007. PMID: 17222708.
2. Lu KH. Gynecologic tumors in hereditary nonpolyposis colorectal cancer: We know they are common-now what? Gynecologic Oncology 82:221-2, 2001.
Other Articles
1. Lu, KH, JE Garber, DW Cramer, WR Welch, J Niloff, D Schrag, RS Berkowitz, M G Muto. Occult ovarian tumors in women with BRCA1 or BRCA2 mutations undergoing prophylactic oophorectomy. Journal of Clinical Oncology/Classic Papers and Current Comments 18(14):2728-2732, 2000.

Abstracts

1. Skates SJ, Drescher CW, Isaacs C, Schildkraut JM, Armstrong DK, Buys SS, Brewster WR, Daly MB, Findelstein DM, Lu KH, ROCA Screening Study Group. A prospective multi-center ovarian cancer screening study in women at increased risk. Proceedings of the American Society of Clinical Oncologists 43rd Annual Meeting 25:5510, 2007.
2. de Souza JA, Wei C, Noguchi S, Lu K, Ishihara H, Aoki D, Ueno NT. Cyclin-dependent kinase (CDK) activity as a prognostic marker in primary epithelial ovarian cancer. Proceedings of the American Society of Clinical Oncology 43rd Annual Meeting 25:#5575, 2007.
3. Maxwell GL, Yurkovetsky Z, Lu K, Lisovich A, Linkov F, Lokshin AE. Development of multimarker panel for early detection of endometrial cancer: High diagnostic power of prolactin. Proceedings of the 38th Annual Meeting of the Society of Gynecologic Oncologist:#287, 2007.
4. Westin SN, Broaddus RR, Lu KH, Lacour RA, Milam MR, Urbauer DL, Nogueras GM, Nabilsi NH, Loose DS. Estrogen-regulated genes in endometrial cancer. Proceedings of the 38th Annual Meeting of the Society of Gynecologic Oncologists:#310, 2007.
5. Basen-Enquist K, Lenihan D, Carmack Taylor C, Lu K, Perkins H, Hughes D, McFalls K, Shin K. Fitness and quality of life in endometrial cancer survivors and controls. Proceedings of the American Society of Clinical Oncology 43rd Annual Meeting 25:#19502, 2007.
6. Wong KK, Tsang YTM, Gu Y, Lu KH, Deavers MT, Malpica A, Gershenson DM. High-resolution global genomic analysis of low-grade serous ovarian tumors reveals novel regions of allelic imbalances. Proceedings of the 38th Annual Meeting of the Society of Gynecologic Oncologists:#102, 2007.
7. Sun CC, Westin SN, Lu KH, Schmeler KM, White KG, Daniels MS, Arun BK, Peterson SK, Bodurka DC. Impact of BRCA 1/2 testing: Body image, sexual functioning, and quality of life (QOL). Proceedings of the American Society of Clinical Oncologists 43rd Annual Meeting 25:#1525, 2007.
8. Soliman PT, Bassett RL, Boyd-Rogers S, Schmeler KM, Slomovitz BM, Gershenson DM, Lu KH. Knowledge of weight and endometrial cancer risk: What women know. Proceedings of the 38th Annual Meeting of the Society of Gynecologic Oncologists:#231, 2007.
9. Slomovitz BM, Burke T, Lu KH, Wolf J, Johnston T, Wu W, Cleestino J, Schmeler K, Soliman P, Broaddus R, Walker C. Loss of PTEN expression associated with response to RAD001 (mTOR inhibitor) in patients with recurrent endometrial cancer: Translational evaluation from a phase II study. Proceedings of the 38th Annual Meeting of the Society of Gynecolgoic Oncologists:#70, 2007.
10. Westin SN, Sun CC, Lu KH, Schmeler KM, Soliman PT, White KG, Daniels NS, Arun BK, Peterson SK, Bodurka DC. Management strategies for women at high risk for breast and ovarian cancer: Are women satisfied?. Proceedings of the American Society of Clinical Oncology 43rd Annual Meeting 25:#1524, 2007.
11. Lacour RA, Urbauer DL, Nongueras-Gonzalez GM, Lu KH, Westin SN, Milam MR, Loose DS, Soliman PT, Schmeler KM, Wu W, Broaddus RR, Nabilsi NH. Molecular abnormalities in histologically normal endometrium of obese women. Proceedings of the 38th Annual Meeting of the Society of Gynecologic Oncologists:#67, 2007.
12. Milam MR, Sun CC, Landen CN, Schmeler KM, Lu KH, Coleman RL, Ramirez PT. Neoadjuvant chemotherapy improves perioperative outcomes in patients with advanced epithelial ovarian cancer. Proceedings of the 38th Annual Society of Gynecologic Oncologist Meeting:#160, 2007.
13. Burke TW, Navo MA, Smith JA, Jung MS, Broaddus R, Iyer RB, Lu KH, Sun CC, Atkinson EN, Ramondetta LM. Phase II trial of mifepristone (RU-486) in advanced or recurrent endometrioid adenocarcinomas or low-grade endometrial stromal sarcoma (LGESS). Proceedings of the American Society of Clinical Oncologists 43rd Annual Meeting 25:#5595, 2007.
14. Lu K, Loose D, Lynch H, Lee-May C, Boyd-Rogers S, Rubin M, Daniels M, Blanco AM, Conrad P, White K, Munsell M, Broaddus R. Preliminary analysis of a prospective, multi-center endometrial cancer chemoprevention study in women with Lynch Syndrome. Proceedings of the 2nd Biennial Scientific Meeting of International Society of Gastrointestinal Hereditary Tumours (InSiGHT, Japan) March, 2007.
15. Moore RG, Brown AK, Miller CM, Badgwell D, Lu Z, Verch T, Lu KH, Allard JW, Granai CO, Bast R. A novel multiple biomarker assay for the detection of ovarian carcinoma. Proceedings of the American Society of Clinical Oncologists 42nd Annual Meeting 24:5023, 2006.
16. Schmeler K, Sun C, Bodurka DC, White K, Soliman PT, Uyei AR, Erlichman J, Arun B, Peterson S, Milam M, Slomovitz B, Gershenson DM, Lu K. Are women with BRCA1/2 mutations choosing prophylactic bilateral salpingo-oophorectomy over surveillance?. Proceedings of the Society of Gynecologic Oncologists 37th Annual Meeting #245:S107, 2006.
17. Schmandt R, Bennett M, Clifford S, Thornton A, Broaddus R, Jiang F, Lu K, Sood AK, Gershenson DM, Gray J. BRK/PTK6 is frequently amplified and promotes tumor growth in ovarian carcinoma. Proceedings of the Society of Gynecologic Oncologists 37th Annual Meeting #228:S99, 2006.
18. Uyei AR, Broglio KR, Solomon TL, Vogel KJ, Amos DI, Lu K, Meric-Bernstam F, Strong L, Arun B. Clinical factors that affect breast cancer risk reduction decisions in high risk women tested for the BRCA 1/2 genetic mutation. Proceedings of the American Society of Clinical Oncologists 42nd Annual Meeting 24:#1013, 2006.
19. Milam M, Slomovitz B, Schmeler K, Soliman PT, Ramirez P, Sun C, Eifel P, Ramondetta L, Lu K. Management and patterns of recurrence of women with occult stage II endometrioid endometrial cancer. Proceedings of the Society of Gynecologic Oncologists 37th Annual Meeting #413:S177, 2006.
20. Slomovitz B, Lu K, Burke TW, Soliman PT, Schmeler K, Munsell M, Johnston T, Coleman R, Ramondetter L, Gershenson DM, Solf J. mTOR is a rational target for the treatment of endometrial cancer: Preliminary results of a phase II study of RAD001 for patients with recurrent endometrial cancer. Proceedings of the Society of Gynecologic Oncologists 37th Annual Meeting #253:S110, 2006.
21. Schmeler K, Broaddus R, Sun C, Soliman PT, Milam M, Thornton A, Wu W, Slomovitz B, Gershenson DM, Lu K, McCampbell A, Shipley G. Obesity related endometrial cancers are not molecularly distinct from endometrial cancers arising in normal weight women. Proceedings of the Society of Gynecologic Oncologists 37th Annual Meeting #233:S101, 2006.
22. Sun CC, Peterson SK, White KG, Watts BG, Daniels MS, Boyd-Rogers SG, Schmeler KM, Bodurka DC, Lu KH. Preferences for cancer prevention strategies (CPS) in women with hereditary nonpolyposis colorectal cancer (HNPCC). Proceedings of the American Society of Clinical Oncologists 42nd Annual Meeting 24:#1018, 2006.
23. Schmeler K, Tortolero-Luna G, Soliman PT, Sun C, Milam M, Slomovitz B, Gershenson D, Lu K, Williams M, Betts P. Racial and ethnic differences in survival among Texas women with ovarian cancer: A population based study. Proceedings of the Society of Gynecologic Oncologists 37th Annual Meeting #143:S63, 2006.
24. Soliman PT, Tortolero-Luna G, Schmeler K, Milam M, Slomovitz B, Sun C, Brown J, Gershenson D, Lu K, Williams M, Betts P. Racial differences in survival among Texaswomen with endometrial cancer: A population-based study. Proceedings of the Society of Gynecologic Oncologists 37th Annual Meeting #182:S80, 2006.
25. Milam M, Celestino EJ, Slomovitz B, Schmeler K, Soliman PT, Broaddus R, Gershenson D, Wu W, Ellenson L, Lu K. Reduced progression of endometrial hyperplasis in PTEN heterozygote mice treated with the oral mTOR inhibitor RAD001. Proceedings of the Society of Gynecologic Oncologists 37th Annual Meeting 17:59, 2006.
26. Milam MR, Ramirez P, Lu K, Bassett R Jr, Coleman R, Slomovitz B, Sood AK. Supracervical hysterectomy does not impact clinical outcome in patients with epithelial ovarian cancer: A case-control analysis. Proceedings of the Society of Gynecologic Oncologists 37th Annual Meeting #362:S155, 2006.
27. Moore RG, Brown Ak, Miller CM, Badgwell D, Lu Z, Verch T, Allard JW, Granai CO, Bast R, Lu K. Utility of a novel serum tumor biomarker HE4 in patients with uterine cancer. Proceedings of the American Society of Clinical Oncologists 42nd Annual Meeting 24:5036, 2006.
28. Lu KH, Watts BG, Soliman PT, Boyd-Rogers SG, Daniels MS, Broaddus RR, Lynch PM, Peterson SK. A prospective pilot study of combined colon and endometrial cancer screening in women with HNPCC. Familial Cancer 4(Suppl 1):104-105, 2005.
29. PT Soliman, Wu D, Tortolero-Luna G, Schmeler KM, Slomovitz BM, Gershenson DM, Lu KH. Adiponectin as a marker for insulin resistance and endometrial cancer risk. Proceedings of the Society of Gynecologic Oncologists' 36th Annual Meeting:100 (#61), 2005.
30. Wu W, Soliman PT, Schmeler KM, Celestino J, Johnson CL, Walker CL, Lu KH. Association between loss of PTEN and cytoplasmic localization of p27 in endometrial cancer. Proceedings of AACR:#2866, 2005.
31. Slomovitz BM, Ramondetta LM, Crotzer D, Schmeler K, Broaddus RR, Sun CC, Gershenson DM, Burke TW, Lu KH. Clinical and pathologic review of clear cell carcinoma of the endometrium: A single institution study of 81 patients. Proceedings of the Society of Gynecologic Oncologists' 36th Annual Meeting:110 (#92), 2005.
32. Lu KH, Schorge JO, Rodabaugh KJ, Sun CC, Daniels MS, White KG, Soliman PT, Luthra R, Broaddus RR. Defining criteria for Lynch Syndrome/HNPCC in women under 50 with endometrial cancer: Final results of a prospective, multi-center study. Proceedings of the American Society of Clinical Oncology 41st Annual Meeting Vol. 23 (#9547), 2005.
33. Schmeler KM, Soliman PT, Sun CC, Oh JC, Slomovitz BM, Gershenson DM, Lu KH. Defining endometrial cancer risk factors for young, non-obese women. Proceedings of the Society of Gynecologic Oncologists’ 36th Annual Meeting:150 (#240), 2005.
34. Slomovitz BM, Coleman RL0, Soliman PT, Ramondetta LM, Wolf J, Sun CC, Gershenson DM, Burke TW, Lu KH. Is there a survival difference between clear cell and serous carcinoma of the endometrium? A stage and age-matched cohort study. Proceedings of the American Society of Clinical Oncology 41st Annual Meeting Vol. 23 (#5081), 2005.
35. Soliman PT, Schmeler KM, Broaddus RR, Slomovitz BM, Wu W, Gershenson DM, Lu KH. MTOR inhibition as a potential treatment for progesterone refractory endometrial nhyperplasia. Proceedings of the American Society of Clinical Oncology 41st Annual Meeting, Vol. 23 (#5080), 2005.
36. Broaddus RR, Green JS, Lynch HT, Chefn LM, Daniels MS, Conrad P, Munsell MF, White KG, Lutha R, Lu KH. Pathologic features of endometrial cancer associated with hereditary non-polyposis colorectal cancer. Familial Cancer 4(Suppl 1):76, 2005.
37. Slomovitz BM, Burke TW, Soliman PT, Ramondetta LM, Eifel PJ, Jhingran A, Wolf J, Sun CC, Gershenson DM, Lu KH. Patterns of recurrence of uterine papillary serous carcinoma. Proceedings of the Society of Gynecologic Oncologists' 36th Annual Meeting:108 (#83), 2005.
38. Lee CM, Slomovitz BM, Greer M, Sheena S, Gregurich MA, Burke T, Lu KH, Ramondetta LM. Practice patterns of SGO members for stage IIIA endometrial cancer. Proceedings of the Society of Gynecologic Oncologists' 36th Annual Meeting:132 (#173), 2005.
39. Schmeler KM, Soliman PT, Munsell MF, Daniels MS, White KG, Boyd-Rogers SG, Sun CC, Slomovitz BM, Gershenson DM, Lu KH. Prophylactic surgery for the reduction of gynecologic cancer risk in women with Lynch Syndrome/HNPCC. Proceedings of the American Society of Clinical Oncology 41st Annual Meeting Vol. 23 (#9531), 2005.
40. Soliman PT, Broaddus RR, Schmeler KM, Gonzalez D, Slomovitz BM, Gershenson DM, Lu KH. Synchronous primary cancers of the endometrium and ovary: Do these women have HNPCC?. Familial Cancer 4(Suppl 1):128, 2005.
41. Soliman PT, Slomovitz BM, Sun CS, Gershenson DM, Lu KH. Endometrial cancer screening should be considered in women with colon cancer and one family member with HNPCC-related cancer. Proceedings of the Society of Gynecologic Oncologists 35th Annual Meeting Vol. 92:434 (#90), 2004.
42. Oh JC, Slomovitz BM, Soliman PT, Jhingran A, Lu KH. Endometrial cancer with ovarian involvement: does it matter if it is metastatic of dual primary?. Proceedings of the Society of Gynecologic Oncologists 35th Annual Meeting Vol. 92:437 (#97), 2004.
43. Lu KH, Dinh M, Kohlmann W, Watson P, Green J, Syngal S, Bandipalliam P, Chen L, Allen B, Conrad P, Terdiman J, Burke TW, Gershenson DM, Lynch H, Lynch P, Broaddus RR. Gynecological malignancy as a "Sentinel Cancer" for women with HNPCC. Proceedings of the Society of Gynecologic Oncologists 35th Annual Meeting, Vol. 92:421 (#61), 2004.
44. Slomovitz BM, Broaddus RR, Burke TW, Sneige N, Soliman PT, Tarco E, Sun C, Wu W, Gershenson DM, Lu KH. Her-2/neu expression and amplification in uterine papillary serous carcinoma (UPSC). Proceedings of the Society of Gynecologic Oncologists 35th Annual Meeting Vol. 92:435-436 (#93), 2004.
45. Ramondetta LM, Slomovitz BM, Caudell JJ, Lu KH, Broaddus RR, Gershenson DM, Deavers MT. Imatinib Mesylate (Gleevec)-targeted kinases are expressed in uterine sarcomas. Proceedings of the Society of Gynecologic Oncologists 35th Annual Meeting Vol. 92:481 (#196), 2004.
46. Oh JC, Wu W, Tortolero-Luna G, Broaddus RR, Gershenson DM, Burke TW, Lu KH. Increased plasma levels of IGF-2 and IGFBP-3 are associated with endometrial cancer risk. Proceedings of the Society of Gynecologic Oncologists 35th Annual Meeting Vol. 92:441-442 (#107), 2004.
47. Slomovitz BM, Wu W, Broaddus RR, Soliman PT, Celestino J, Thornton A, Wolf JK, Gershenson DM, Lu KH. Preclinical assessment of mTOR inhibition: A novel therapeutic target for the treatment of endometrial cancer. Proceedings of the Society of Gynecologic Oncologists 35th Annual Meeting Vol. 92:47-478 (#188), 2004.
48. Skates SJ, Horick NK, Finkelstein DM, Lu KH. Prospective multi-center high risk ovarian cancer screen trial: preliminary results from the first 2,000 women. Proceedings of the Society of Gynecologic Oncologists 35th Annual Meeting Vol. 92:411 (#39), 2004.
49. Chung LH, Broaddus RR, Vay A, Thornton A, Suh-Bergman B, Lu KH. PTEN expression increases in atypical endometrial hyperplasia successfully treated with progesterone. Proceedings of the Society of Gynecologic Oncologists 35th Annual Meeting, Vol. 92:484-485 (#204), 2004.
50. Soliman PT, Slomovitz BM, Broaddus RR, Sun CC, Oh JC, Gershenson DM, Lu KH. Synchronous primary cancers of the endometrium and ovary: A single institution review of 76 cases. Proceedings of the Society of Gynecologic Oncologists 35th Annual Meeting Vol. 92:482-483 (#199), 2004.
51. Slomovitz BM, Ramirez PT, Bodurka DC, Sun CC, Oh JC, Diaz P, Broaddus RR, Soliman PT, Gershensom DM, Lu KH. Tamoxifen use affect prognosis in breast cancer patients who develop endometrial cancer?. Proceedings of the Society of Gynecologic Oncologists 35th Annual Meeting Vo. 92:404-405 (#24), 2004.
52. Lu K, Symecko H, Skates S, Finkelstein D. Cancer genetics network ovarian screening study: Physician practice patterns in screening women at high risk for ovarian cancer. Proceedings of the American Society of Clinical Oncology 39th Annual Meeting, Vol. 22 (#1972), 2003.
53. Slomovitz B, Ramirez P, Bodurka D, Diaz P, Oh J, Burke T, Gershenson D, Lu K. Characteristics of endometrial carcinoma in patients with a history of breast cancer. Proceedings of the American Society of Clinical Oncology 39th Annual Meeting Vol. 22 (#1867), 2003.
54. Slomovitz B, Oh J, Eifel P, Broaddus R, Silva E, Atkinson E, Burke T, Gershenson D, Lu K. Clinical and Pathologic Characteristics of Uterine Papillary Serous Carcinoma: Single Institution Review of 128 Cases. Gynecologic Oncology 88:p210 (#111), 2003.
55. Shvartsman H, Bodurka D, Sun C, Crispens M, Lu K, Silva E, Gershenson D. Comparative study of disease process and survival in patients with recurrent serous low malignant potential tumor of ovary versus low grade serous carcinoma. Proceedings of the American Society of Clinical Oncology 39th Annual Meeting Vol. 22 (#1818), 2003.
56. Oh J, Slomovitz B, Broaddus R, Gershenson D, Burke T, Schmandt R, Lu K. Endometrial Cancer in Patients under 50: 161 Patients from a single institution. Gynecologic Oncology 88:218 (#129), 2003.
57. Lee C, Slomovitz B, Fletcher M, Hung M, Lu K, Sood A. Experimental/Molecular therapeutics 27: Target identification and Cell Cycle Mechanisms. Proceedings of the American Association for Cancer Research 94th Annual Meeting Vol. 44 (#2762), 2003.
58. Wang L, Liu J, Jain A, Luo R, Rosen D, Lu K, Yu Y, Bast R Jr. Expression of the tumor suppressor gene ARHI is maintained in well differentiated ovarian cancers and is associated with increased expression of p21WAF1/CIP1. Proceedings of the American Association for Cancer Research 94th Annual Meeting, Vol. 44 (#4941), 2003.
59. Slomovitz B, Celestino J, Chung L, Thornton A, Lu K. Frequent down-regulation of cdc25B and phosphorylated estrogen receptor alpha correlate with high-grade endometrial carcinomas. Proceedings of the American Association for Cancer Research 94th Annual Meeting Vol. 44 (#2301), 2003.
60. Marquez R, Baggerly K, Patterson A, Frumovitz M, Atkinson E, Liu J, Smith D, Hartmann L, Fishman D, Berchuck A, Whitaker R, Gershenson D, Mills G, Bast R Jr, Lu K. Gene expression array analysis distinguishes different histotypes of epithelial ovarian cancer and suggests a distinct transcriptional program for mucinous cancers. Proceedings of the American Association for Cancer Research 94th Annual Meeting Vol. 44 (#2525), 2003.
61. Slomovitz B, Broaddus R, Thornton A, Oh J, Celestino J, Schmandt R, Burke T, Gershenson D, Lu K. Gleevec (Imatinib Mesylate) Targeted Kinases Are Activated in Most Endometrial Cancers. Gynecologic Oncology 88:207 (#106), 2003.
62. Slomovitz B, Lu K, Wu W, Oh J, Schmandt R, Celestino J, Thornton A, Gershenson D, Loose-Mitchell D, Broaddus R. IGF-1 receptor expression in endometrial carcinoma. Proceedings of the American Association for Cancer Research 94th Annual Meeting, Vol. 44 (#498), 2003.
63. Slomovitz B, Lu K, Wu W, Oh J, Schmandt R, Celestino J, Thornton A, Gershenson D, Loose-Mitchell D, Broaddus R. IGF-1 receptor expression in endometrial carcinoma. Proceedings of the American Association for Cancer Research 94th Annual Meeting 44:#498, 2003.
64. Hartmann LC, Couch FJ, Kaufmann SH, Cliby WA, Iturria SJ, Kalli KR, Lu K, Bast B, Lillie J, Stec J, Shridhar V, Smith DI, Clark E. Chemoprediction in Ovarian Cancer-Genomic Approaches. Proceedings of the Society of Gynecologic Oncologist 33rd Annual Meeting:74 (#p 17), 2002.
65. Weigui W, Lu K, Liu J, Yung MS, Vincent M, Kudelka AP, Freedman R, Kavanagh J. Differential protein profile analysis of sera from normal donors and ovarian cancer patients by proteomics. Proceedings of the American Association for Cancer Research 93rd Annual Meeting, Vol. 43 (#189), 2002.
66. Malpica A, Deavers MT, Lu K, Liu J, Atkinson EN, Gershenson DM, Silva EG. Grading Ovarian Serous Carcinomas Using a Two-Tier System. Modern Pathology 15 (#849), 2002.
67. Vidal CI, Broaddus RR, Lu KH, Ellis LM, Arap W, Pasqualini R. Identification of molecular markers in ovarian cancer. Proceedings of the American Association for Cancer Research 93rd Annual Meeting, Vol. 43 (#3013), 2002.
68. Lee CM, Shvartsman H, Deavers MT, Xias W, Bodurka DC, Atkinson EN, Malpica A, Gershenson DM, Hung MC, Lu K. Immunohistochemical analysis of b-catenin localization in low-grade and high grade serous ovarian carcinomas. Proceedings of the ASCO Volume 21:300 (#3018), 2002.
69. Oh J, Broaddus R, Totolero G, Gershenson DM, Burke TW, Schmandt R, Lu K. Insulin-like growth factors and endometrial cancer. Proceedings of the ASCO Vol 21:220a (#p 876), 2002.
70. Lu K, Kohlman W, Lynch P, Chen L, Allen B, Terdiman J, Lynch H, Tinley S et al. A consortium to study endometrial cancer in women with HNPCC. Proceedings of the 3rd Joint Meeting Leeds Castle Polyposis Group and International Collaborative Group Hereditary Non-Polyposis Colorectal Cancer:32, 2001.
71. Schmandt RE, Clifford SL, Lee J, Lillie J, Deavers M, Shaw P, Jung M, Levenback C, Bast R, Mills G, Gershenson DM, Lu KH. Differential expression of the secreted protease inhibitor, HE4, in epithelial ovarian cancer. Society of Gynecologic Oncologists 80:319, 2001.
72. Lu K, Dinh M, Kohlmann W, Watson P, Green J, Syngal S, Bandipalliam P, Chen L, Allen B, Conrad P, Terdiman J, Burke T, Gershenson D, Lynch H, Lynch P, Broaddus R. Gynecological Malignancy as a "Sentinel Cancer" for Women with HNPCC. American Journal of Human Genetics 69:251, 2001.
73. Lu KH, Malpica AM, Bodurka-Bevers D, Shvartsman HS, Schmandt RE, Thornton A, Deavers MT, Silva EG, Gershenson DM. Immunohistochemical analysis of low grade serous ovarian carcinomas. Society of Gynecologic Oncologists 80:320, 2001.
74. Shvartsman HS, Lu KH, Clifford SL, Lee J, Lillie J, Deavers M, Jung M, Bast R, Mills G, Gershenson DM, Schmandt RE. Overexpression of NES-1 in epithelial ovarian cancer. Gynecol Oncol 80:319, 2001.
75. Gershenson DM, Tortolero-Luna GT, Deavers MT, Lu K, Wolf JK, Malpica A, Silva EG. Prognostic factors for relapse and survival in patients with stage II or III serous borderline ovarian tumors (BOT). Society of Gynecologic Oncology Abstract 76:240, 2000.
76. Bodurka-Bevers D, Lu K, Wolf JK, Bevers MW, Branham D, Silva EG, Gershenson DM. The clinical course of low-grade serous carcinomas of the ovary. Gynecol Oncol 76:254, 2000.
77. Lu KH, Garber J, Cramer D, Welch W, Berkowitz R, Muto M. Prophylactic oophorectomies in women at high risk for ovarian cancer. Proceedings of the Society of Gynecologic Oncologists Annual Meeting, 1999.
78. Lu KH, Cramer D, Muto M, Li E, Niloff J, Mok S. Frequency of BRCA1 mutations 185delAG and 5382insC and BRCA2 mutation 617delT in Ashkenazi Jewish women with epithelial ovarian cancer. Proceedings of the Society of Gynecologic Oncologists Annual Meeting 1998, 1998.
79. Lu KH, Bell D, Welch W, Berkowitz R, Mok S. Evidence for the multifocal origin of serous borderline ovarian tumors. Proceedings of the American Association for Cancer Research Annual Meeting, 1997.
80. Laufer MR, Townsend NL, Parsons KE, Brody KA, Lu KH, Diller LR, Emans SJ, Guinan EC. The use of leuprolide acetate for the induction of amenorrhea in women undergoing bone marrow transplantation (BMT): A pilot study. Proceedings of the American Society of Clinical Oncology Annual Meeting, 1995.

Book Chapters

1. Mok SC, Wong KK, Lu K, Munger K, Nagymanyoki Z. Molecular Basis of Gynecologic Diseases. In: Essential Concepts in Molecular Pathology. Chapter 23. Ed(s) WR Coleman and GJ Tsongalis. Academic Press: Burlington, MA, 309-322, 2010.
2. Lu KH. Clinical Relevance of Hereditary Endometrial Cancer. In: Hereditary Gynecologic Cancer: Risk, Prevention, and Management. Informa Healthcare: New York City, NY, 2008.
3. Lu KH. Karen H. Lu, MD. In: Legends and Legacies: Personal Journeys of Women Physicians and Scientists at M.D. Anderson Cancer Center. Ed(s) EL Travis, PhD. The U T M.D. Anderson Cancer Center: Houston, TX, 107-115, 2008.
4. Lu KH, Keeler ER. Ovarian Cancer Screening. In: Early Diagnosis of Ovarian Cancer. Elsevier: Philadelphia, Pennsylvania, 2008.
5. Lu KH, Broaddus R. Endometrial Cancer Associated with Defective DNA Mismatch Repair. In: Prognostic and Predictive Factors in Gynecologic Cancers. Ed(s) C Levenback, R Coleman, K Lu, A Sood. Informa UK, Ltd: London, England, 185-196, 2007.
6. Lu KH, Skates S. Hereditary Breast Cancer. In: Prognostic and Predictive Factors in Gynecologic Cancers. Ed(s) T Rebbick, C Isaccs. Informa UK Ltd: London, England, 2007.
7. Lu KH, Slomovitz B. Neoplastic Diseases of the Uterus. In: Comprehensive Gynecology. Chapter 32, 5th. Ed(s) VL Katz, G Lentz, R Lobo, D Gershenson. Informa UK Ltd: Longdon, England, 818-838, 2007.
8. Lu KH. Organ Specific Cancer Control. In: Gynecologic Cancers, ASCOs Cancer Prevention Curriculum, 2007.
9. Lu KH. Prevention and Early Detection of Endometrial and Ovarian Cancers. In: Gynecologic Cancer. Chapter 2. Ed(s) PJ Eifel, DM Gershenson, JJ Kavanagh, EG Silva. Spring Scient and Business Media Inc, 12-19, 2006.
10. Lu KH, Bell D. Borderline Ovarian Tumors. In: Gynecologic Cancer: Controversies in Management,. Elsevier Ltd,, Pg 519-526, Chapter 40, 2004.
11. Ramondetta, LM, Lu KH. Controversies in endometrial cancer screening and diagnosis. . In: Gynecologic Cancer: Controversies in Management. Pg 241-247. Elsevier Ltd, Chapter 17, 2004.
12. Lu KH, Gershenson DM, Poynor EA, Sabbatini PJ. Germ-cell and ovarian sex cord-stromal tumors. In: MSKCC-MDACC Handbook of Gynecologic Oncology. Martin Dunitz Publishers, Ltd., Pg 271-82, Chapter 15, 2002.
13. Burke TW, Lu KH. Surgical Treatment of Invasive Cervical Cancer. In: ACS Atlas of Clinical Oncology: Cancer of the Female Lower Genital Tract. B.C. Decker Inc., 133-145, 2001.

Books (edited and written)

1. Lu KH. Ed(s) KH Lu. Hereditary Gynecologic Cancer: Risk, Prevention and Management. Informa NYC: New York, NY, 2008.
2. C Levenback, R Coleman, K Lu, A Sood. Prognostic and Predictive Factors in Gynecologic Cancers. Informa UK Ltd: London, England, 2007.

Manuals, Teaching Aids, Other Teaching Publications

1. Lu K. Understanding endometrial cancer: A woman's guide. Gynecologic Cancer Foundation, 2006.
2. Lu K. Ovarian Cancer Educational CD-ROM Series. TLM Japan, 2005.
3. Lu K, Smith JA. Chemotherapy Regimens for Gynecologic Malignancies, 2003.

Grant & Contract Support

Title: M. D. Anderson Cancer Center Gynecologic Cancer SPORE for Uterine Cancers
Funding Source: NIH/NCI
Role: Principal Investigator
Duration: 9/1/2010 - 8/31/2015
 
Title: Lipotoxicity and Obesity Related Risk of Endometrial Carcinoma
Funding Source: UTHSC-Houston
Role: Co-Principal Investigator
Principal Investigator: Perry Bickel, MD
Duration: 9/1/2008 - present
 
Title: Predictors of Survival: Chemotherapy in Ovarian Cancer
Funding Source: DOD/Congressionally Directed Medical Research Programs (DOD/CDMRP)
Role: Principal Investigator-MDACC
Principal Investigator: Dong Liang, PhD
Duration: 7/1/2007 - 6/30/2012
 
Title: M. D. Anderson Cancer Center-Ciphergen Collaboration in the Field of Gynecologic Disease
Funding Source: Ciphergen Biosystems, Inc.
Role: Principal Investigator
Duration: 10/1/2006 - 11/30/2007
 
Title: UPRCC/NDACC: Partnership for Excellence in Cancer Research
Funding Source: NIH/NCI
Role: Principal Investigator-Pilot Project C
Principal Investigator: Gabriel Lopez-Berestein, MD
Duration: 9/22/2006 - 8/31/2012
 
Title: Ovarian Cancer Proteomics Collaborative Trial
Funding Source: NIH/NCI
Role: Principal Investigator-MDACC
Duration: 9/1/2005 - 8/31/2008
 
Title: The Lynne Cohen High Risk Screening & Prevention Project for Ovarian and Breast Cancer
Funding Source: The Lynne Cohen Foundation for Ovarian Cancer Research
Role: Principal Investigator
Duration: 4/1/2005 - 8/31/2012
 
Title: Annual Uterine Cancer Symposium
Funding Source: NIH/NCI
Role: Principal Investigator
Duration: 9/1/2004 - 8/31/2011
 
Title: Ovarian Cancer Screening Trial in High Risk Women (Cancer Genetics Network/CGN)
Funding Source: NIH/NCI
Role: Principal Investigator-MDACC
Principal Investigator: Steven Skates, MD
Duration: 7/1/2004 - 6/30/2008
 
Title: Endometrial Cancer Translational Research Program
Funding Source: UT M. D. Anderson Cancer Center Multidisciplinary Research Program (MRP)
Role: Principal Investigator
Duration: 5/1/2002 - present
 
Title: Modulation of putative surrogate endpoint biomarkers in endometrial biopsies from women with HNPCC
Funding Source: NIH/NCI
Role: Principal Investigator
Duration: 9/30/2000 - 9/30/2009
 
Title: Specialized Program of Research Excellence in Ovarian Cancer
Funding Source: NIH/NCI
Role: Project Leader
Principal Investigator: Robert C. Bast, M.D.
Duration: 9/30/1999 - 8/31/2016

Last updated: 4/27/2016